Alzheimer's Disease Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | BioVie, AB Science, Cassava, TauRx, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim, AgeneBio, Eisai, Syneos, Annovis Bio, Anavex

The Alzheimer's disease market size in the 7MM was approximately USD 3,460.6 million in 2022 and is projected to increase during the forecast period (2023-2032). As per DelveInsight, the Alzheimer's Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Alzheimer's Disease and the launch of new therapies in the market.

Some of the potential emerging therapies such as BioVie's NE3107, Cassava Sciences' simufilam (PTI-125), Anavex Life Sciences' ANAVEX2-73 (blarcamesine), Alzheon's ALZ-801 (valiltramiprosate) among others are expected to enter the market in the near future.

DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alzheimer's Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Alzheimer's Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alzheimer's Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Alzheimer's Disease: An Overview
Alzheimer's disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer's patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.

Alzheimer's disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die. The most well-known risk factor for Alzheimer's disease is age. Alzheimer's disease is not a natural part of aging, but it does increase the chances of developing it as the person gets older. It is accompanied by a family history of the said disease, or it is also observed that many people with down's syndrome experience Alzheimer's later in their life.

Alzheimer's Disease Market Key Facts
• Among the 7MM, the US had the largest market share in Alzheimer's disease, with a revenue of USD 1,751.7 million in 2022. The market size of Alzheimer's disease in the US will increase at a significant CAGR due to increasing awareness of the disease and the launch of the emerging therapy.
• The total market size of Alzheimer's disease in EU4 and the UK was calculated to be USD 794.4 million in 2022, which was approximately 23.0% of the total market revenue for the 7MM. Among EU4 and the UK countries, Germany accounted for the maximum market size of Alzheimer's disease in 2022, while the UK occupied the bottom of the ladder.
• Japan accounted for the second-largest market of Alzheimer's disease among the 7MM, with a revenue of approximately USD 914.5 million in 2022, expected to increase during the forecast period.
• DelveInsight estimates that ADUHELM accounted for USD 4.6 million in the US in 2022. This revenue is projected to increase with hopes for traditional approval.
• In 2022, the total diagnosed prevalent cases of Alzheimer's disease were estimated to be approximately 15,083,370 cases in the 7MM.
• In the US, there were approximately 6,186,284 diagnosed prevalent cases of Alzheimer's disease in 2022. These were nearly 41% of the total cases in the 7MM.
• In 2022, among the 7MM, Japan accounted for the second-highest diagnosed prevalent cases of Alzheimer's disease, contributing nearly 26%, while the UK accounted for the least with nearly 4% of the total diagnosed prevalent cases.
• In 2022, EU4 and the UK accounted for nearly 33% of the total diagnosed prevalent cases of Alzheimer's in the 7MM. There were approximately 4,942,376 total diagnosed prevalent cases of Alzheimer's disease.
• Among EU4 and the UK, Germany accounted for the highest (nearly 31%) total diagnosed prevalent cases of Alzheimer's disease, with approximately 1,510,515 cases, followed by France (nearly 24%).

Discover How Alzheimer's Disease Market Will Grow by 2032:
https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alzheimer's Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alzheimer's Disease therapies in the market. It also provides a detailed assessment of the Alzheimer's Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Alzheimer's Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Alzheimer's Disease Epidemiology
The epidemiology section covers detailed insights into the historical, and current Alzheimer's Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Alzheimer's Disease Epidemiology Segmented as -
• Total prevalent cases of Alzheimer's Disease (AD) in the 7MM [2019-2032]
• Total diagnosed prevalent cases of Alzheimer's disease in the 7MM [2019-2032]
• Total age-specific diagnosed prevalent cases of Alzheimer's Disease in the 7MM [2019-2032]
• Total severity-specific diagnosed prevalent cases of Alzheimer's Disease in the 7MM [2019-2032]
• Total treated cases of Alzheimer's Disease in the 7MM [2019-2032]
• Total gender-specific diagnosed prevalent cases of Alzheimer's Disease in the 7MM [2019-2032]

Get Key Insights Into the Evolving Alzheimer's Disease Epidemiology Trends:
https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alzheimer's Disease Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alzheimer's Disease market or expected to be launched during the study period. The analysis covers the market share by Alzheimer's Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Alzheimer's Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alzheimer's Disease Therapeutics Assessment
Alzheimer's disease is a complex neurological issue. Most medications are most effective in patients who are in the early to mid stages of Alzheimer's disease. The prescribed therapies may temporarily slow down certain symptoms, such as memory loss, however, it is important to note that none of these drugs can cure the condition. The U.S. Food and Drug Administration (FDA) has approved pharmacotherapy treatment to relieve the cognitive symptoms (memory loss, uncertainty, and difficulty with rational reasoning) in Alzheimer's patients.

Several major pharma and biotech companies are developing therapies for Alzheimer's disease. Currently, Eli Lilly and Company is leading the therapeutics market with its Alzheimer's disease drug candidates in the most advanced stage of clinical development.

Various therapies like Anavex Life Sciences's ANAVEX2-73 (blarcamesine), Alzheon's ALZ-801 (valiltramiprosate), Athira Pharma's fosgonimeton (ATH-1017), Annovis Bio's buntanetap, Eli Lilly's donanemab (LY3002813), BioVie's NE3107, Cassava Sciences' simufilam (PTI-125), and TauRx Therapeutics' hydromethylthionine mesylate (TRx0237) among others are anticipated to enter the market during the forecast period.

Leading Companies in the Alzheimer's Disease Therapeutics Market Include
• BioVie
• AB Science
• Cassava Sciences
• Eli Lilly
• TauRx Therapeutics
• Novo Nordisk
• KeifeRx
• Eli Lilly
• AriBio
• Cerecin
• Alzheon
• Neurim Pharmaceuticals/Syneos Health
• Athira Pharma
• Annovis Bio
• Anavex Life Sciences
• AgeneBio
• Eisai
And Many Others

Emerging and Marketed Alzheimer's Disease Therapies Covered in the Report Include
• ADUHELM (aducanumab): Biogen and Eisai
• LEQEMBI (lecanemab): Biogen and Eisai
• NE3107: BioVie
• Donanemab (LY3002813): Eli Lilly
• Simufilam (PTI-125): Cassava Sciences
• Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
• ALZ-801 (valiltramiprosate): Alzheon
• Fosgonimeton (ATH-1017): Athira Pharma
• Buntanetap: Annovis Bio
• ANAVEX2-73 (blarcamesine): Anavex Life Sciences
And Many More

Learn More About the Emerging Therapies & Key Companies in the Alzheimer's Disease Therapeutics Market:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alzheimer's Disease Competitive Intelligence Analysis
4. Alzheimer's Disease Market Overview at a Glance
5. Alzheimer's Disease Background and Overview
6. Alzheimer's Disease Patient Journey
7. Alzheimer's Disease Epidemiology and Patient Population
8. Alzheimer's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer's Disease Unmet Needs
10. Key Endpoints of Alzheimer's Disease Treatment
11. Alzheimer's Disease Marketed Products
12. Alzheimer's Disease Emerging Therapies
13. Alzheimer's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Alzheimer's Disease Market Outlook (7 major markets)
16. Alzheimer's Disease Access and Reimbursement Overview
17. KOL Views on the Alzheimer's Disease Market.
18. Alzheimer's Disease Market Drivers
19. Alzheimer's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market

Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market

Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Respiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market

Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Traveler's Diarrhea Market
https://www.delveinsight.com/report-store/travelers-diarrhea-market

Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market

Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.